Intradermal Influenza Vaccine in the Young

Status Completed

Clinical Trial Summary

Influenza poses a heavy burden to our health service. The WHO estimates that seasonal influenza causes 250,000-500,000 deaths worldwide each year. Various strategies including intradermal vaccination and new vaccine adjuvants have been shown to improve immunogenicity. Recently, imiquimod, a synthetic Toll-like receptor 7 (TLR7) agonist useful for the treatment of DNA virus infection, have been shown to improve vaccine immunogenicity against influenza virus in mouse model. The objective of this prospective double-blind randomized controlled trial is to evaluate the effect and safety of topical treatment with imiquimod immediately before intradermal influenza vaccination in healthy young adults.

Clinical Trial Description

Influenza poses a heavy burden to our health service. Seasonal, zoonotic and pandemic influenza are constant global threats. The WHO estimates that seasonal influenza causes 250,000-500,000 deaths worldwide each year, with an even higher mortality during the pandemic periods. Moreover zoonotic influenza such as the avian-origin H5N1 and more recently the H7N9 influenza are associated with a much higher mortality than seasonal influenza. Vaccine immunogenicity among elderly individuals is also suboptimal due to immunosenescence. Various strategies including intradermal vaccination and new vaccine adjuvants have been shown to improve immunogenicity.

Recently, imiquimod, a synthetic Toll-like receptor 7 (TLR7) agonist useful for the treatment of DNA virus infection, have been shown to improve vaccine immunogenicity against influenza virus in both mouse model. The objective of this prospective double-blind randomized controlled trial is to evaluate the effect and safety of topical treatment with imiquimod immediately before intradermal influenza vaccination. Our a priori hypothesis is that imiquimod pretreatment would expedite and augment the immunogenicity of influenza vaccination. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02103023
Study type	Interventional
Source	The University of Hong Kong
Contact
Status	Completed
Phase	Phase 3
Start date	March 2014
Completion date	November 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05869201` - Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine	Phase 2/Phase 3
Recruiting	`NCT06123936` - Impact on Influenza Vaccination Rates of a Telephone Text Message Recall From the Attending Physician	N/A
Completed	`NCT05234229` - Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
Completed	`NCT04623047` - Infection Watch Study
Not yet recruiting	`NCT02465190` - Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa	N/A
Completed	`NCT05620953` - Severe Acute Respiratory Infections (SARI) in Belgium (2011-2020)
Recruiting	`NCT05739474` - Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children	Phase 3
Active, not recruiting	`NCT05794412` - Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study
Recruiting	`NCT05557539` - Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach	N/A
Completed	`NCT03813966` - Nasal Swab Home Collection Kit (NSHC Kit) Study
Terminated	`NCT05105191` - Analytical Performances and Clinical Impact of the Roche Cobas® Liat Influenza A/B & RSV Assay in the Management of Adult and Pediatric Patients Attending the Emergency Room	N/A
Not yet recruiting	`NCT06247059` - Reducing Respiratory Virus Transmission in Bangladeshi Classrooms	N/A
Not yet recruiting	`NCT06175468` - Evaluate the Efficacy and Safety of "Formosa 1-Breath Free (NRICM101) " in Subjects With the Symptoms of COVID-19 or Influenza-like Disease	Phase 3
Active, not recruiting	`NCT01666782` - Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy	Phase 2
Completed	`NCT05507567` - Safety, Tolerability and Prophylactic Antiviral Activity of Neumifil Against Influenza Via a Human Viral Challenge Model	Phase 2
Active, not recruiting	`NCT04998344` - An Effectiveness Trial to Evaluate Protection of Children and Pregnant Women by Influenza Vaccine in Rural Bangladesh	Phase 4